Abstract: The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described. When a liquefied hydrofluoroalkane is added to a kneaded premix of the tricyclic compound (I) and a medium-chain fatty acid triglyceride, the active ingredient is evenly dispersed in the liquefied hydrofluoroalkane. Therefore, by distributing a dispenser first with the kneaded premix and, then, with a liquefied hydrofluoroalkane under cooling or elevated pressure, there can be provided a medicinal aerosol composition an improved uniformity of content of the active ingredient.

Abstract: The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described.

Abstract: The use of a medium-chain fatty acid triglyceride as the dispersant in the preparation of a medicinal aerosol composition comprising tricyclic compound (I) dispersed in a liquefied hydrofluoroalkane propellant is described. When a liquefied hydrofluoroalkane is added to a kneaded premix of the tricyclic compound (I) and a medium-chain fatty acid triglyceride, the active ingredient is evenly dispersed in the liquefied hydrofluoroalkane. Therefore, by distributing a dispenser first with the kneaded premix and, then, with a liquefied hydrofluoroalkane under cooling or elevated pressure, there can be provided a medicinal aerosol composition having an improved uniformity of content of the active ingredient.

Abstract: To provide a pharmaceutical composition comprising a water-insoluble active substance, surfactant(s) and solid carrier(s), which is improved in dissolution and oral absorption characteristics.

Abstract: A lotion comprising a tricyclic compound, typically 17-allyl-1,14-dihydroxy-12-?2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l!-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo ?22.3.1.0.sup.4,9 !octacos-18-ene-2,3,10,16-tetraone, or a pharmaceutically acceptable salt thereof, a solubilizing and/or absorption-promoting agent, a liquid medium, and optionally an emulsifier and/or a viscosity increasing agent. The lotion is stable, excellent in absorption and has less irritation against the skin and sustained release. Also, the lotion is effective for the treatment and/or prophylaxis of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.

Abstract: A liposome preparation containing an immunosuppresive tricylic compound or a pharmaceutically acceptable salt thereof. Since the tricyclic compound is entrapped stably and quantitatively into the liposomes, a broad variety of drug forms and pharmaceutical preparations insuring a long duration of efficacy can be provided.

Abstract: This invention relates to an aqueous liquid composition for external use which contains a tricyclo compound of the chemical formula (I) presented here-under or a pharmaceutically acceptable salt thereof. More particularly, the invention relates to an aqueous liquid composition for external use characterized in that it contains said tricyclo compound and a water-soluble solubilizer. The composition of the invention is used in medical treatment.

Abstract: A percutaneously absorbable preparation containing a drug and a percutaneous absorption accelerator comprising a monoglyceride and a fatty acid.

Abstract: This invention relates to an encapsulated pharmaceutical dosage form comprising a practically insoluble compound or salt and an intracapsular fluid, and/or a surfactant and/or cellulose derivative. It provides for increased oral absorption as compared with the conventional system because, on release of capsule contents from the capsule shell, the practically insoluble compound or salt undergoes diminution in crystal size.

Abstract: An external skin treatment agent composition containing an active ingredient comprising a prostacyclin, and/or its optical isomer, having the formula (I): ##STR1## (wherein, R.sup.1 is a hydrogen atom, a straight chain or branched alkyl group of C.sub.1 to C.sub.10, or one equivalent of a cation, R.sup.2 is a substitutable C.sub.1 to C.sub.10 straight chain or branched alkyl group or substitutable C.sub.1 to C.sub.10 straight chain or branched alkenyl group or alkinyl group, R.sup.3 is a straight chain alkyl group of C.sub.1 to C.sub.5, and R.sup.4 and R.sup.5 are independently a hydroxyl group or formula: ##STR2## (where, R.sup.6 is a C.sub.1 to C.sub.5 straight chain or branched alkyl group)) and a carrier.

Abstract: The invention relates to a delayed action preparation which comprises a core comprising a drug and a swelling agent and an outer membrane comprising a biodegradable high molecular weight substance characterized in that the swelling agent is contained in a sufficient amount to cause a explosion of the outer membrane of biodegradable high molecular weight substance at a definite time after administration. This preparation provides for free control over the timing of drug release and is suited for administration not only by the oral route but also by the intramuscular, subcutaneous and other routes.

Abstract: A sustained release medicinal preparation is produced by enclosing a macrocyclic compound represented by 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l)-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1 .0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone or 17-ethyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1 .0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone, into the fine particles generally called microspheres which arc made of biodegradable polymer. This preparation, when, for example, given by injection, appreciably improves the transferance of said macrocyclic compound into the blood. Further, this is also used as an agent suitable for topical administration.

Abstract: A hair revitalizing agent including a compound represented by the formula shown below or a pharmaceutically acceptable salt thereof: ##STR1## (wherein R.sup.1 to R.sup.10, R.sup.14 to R.sup.23, X, Y, and n are the same as defined in the present specification).

Abstract: The present invention relates to liposome preparations. In particular, the present invention relates to Adriamycin-entrapped liposome preparations comprising cholesterol derivatives having a negative charge as a liposome membrane constituent. Adriamycin-entrapped liposome preparations have many uses in the medical field such as maintaining high Adriamycin blood levels over a long period of time and reducing systemic toxicity, for example.

Abstract: The present invention relates to a pharmaceutical composition for percutaneous drug absorption which comprises 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and ethanol and/or an unsaturated higher fatty acid and to a composition of matter which comprises ethanol and/or an unsaturated higher fatty acid and is capable of promoting percutaneous absorption of said dihydropyridine compound.

Abstract: The invention relates to a Time-Controlled Explosion System in which drug release is caused by explosion of a membrane after a definite time period, said System comprising a preparation in the form of a bead or granule, said preparation comprising a core, a drug, swelling agent and an outer membrane of water-insoluble coating material.

Abstract: The invention concerns the preparation of a slow-release drug characterized by the coating of a core comprising a therapeutically active principle by means of a substance which retards its release and by means of an additional layer consisting of an enteric substance.

Abstract: The present invention relates to a multiple soft capsule in which a soft capsule is contained in another soft capsule and the production thereof. The multiple soft capsule is useful for various industrial fields such as medicine, foods, table luxuries and the like. Especially, the multiple capsule is useful in medical field, for instance, in combining two or more components which cannot be enclosed together in a single capsule or in the dissolution control in vivo of the medicines by properly selecting the kind of the film-forming substance for the outer and inner soft capsules.

Abstract: A soft capsule which is prepared by wrapping an oily substance which is a member selected from the group consisting of tricaprylic acid glyceride and sesame oil, with a gelatin film containing sodium picosulfate.

Abstract: The present invention relates to a long active pharmaceutical composition of Tiaramide or its pharmaceutically acceptable salt which comprises Tiaramide or its pharmaceutically acceptable salt as an active ingredient and a water particularly insoluble substance which melts with warming or heating.